Biotech Industry Merger and Acquisition Activity at a Four-Year High
30 August 2012 - 10:20PM
Marketwired
Biotechnology stocks continue to be some of the strongest
performers in the markets as favorable legislation, such as the
FAST and TREAT acts, have helped boost investor optimism within the
industry. The iShares Nasdaq Biotechnology Index Fund (IBB) is up
over 30 percent in 2012 -- handedly outperforming the Dow Jones
industrial average year-to-date. Five Star Equities examines the
outlook for companies in the Biotech Industry and provides equity
research on ImmunoGen, Inc. (NASDAQ: IMGN) and Osiris Therapeutics,
Inc. (NASDAQ: OSIR).
Access to the full company reports can be found at:
www.FiveStarEquities.com/IMGN
www.FiveStarEquities.com/OSIR
The FAST and TREAT acts introduced in 2012 have helped
accelerate the development, review and approval process of
medicines/personalized therapies for patients suffering from
serious and life-threatening diseases. According to recent data
from Thomson Reuters, biotech mergers & acquisitions activity
is currently at a four-year high as large pharmaceuticals are
facing major patent cliffs. So far in 2012 the volume of biotech
M&A has exceeded $25 billion, compared to roughly 10 billion in
the same period of 2011.
"Their patents have expired, and as a result they have holes in
their revenue line they are trying to fill," said Scott Lindsay,
global head of mergers and acquisitions at Credit Suisse. "The
other part is just shoring up the pipeline they have. So even if
they don't have a major patent problem, they're all looking for
growth."
Five Star Equities releases regular market updates on the
Biotech Industry so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.FiveStarEquities.com and
get exclusive access to our numerous stock reports and industry
newsletters.
ImmunoGen develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The company
announced that Roche has reported updated results from its EMILIA
Phase III trial that show patients treated with trastuzumab
emtansine had a significant improvement in OS compared to those
randomized to standard-of-care therapy.
Osiris Therapeutics is a leading stem cell company focused on
developing and marketing products to treat medical conditions in
the inflammatory, autoimmune, orthopedic and cardiovascular areas.
Osiris' stem cell products have significant therapeutic potential
because of their ability to regulate inflammation, promote tissue
regeneration and prevent pathological scar formation.
Five Star Equities provides Market Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. Five Star Equities has not been compensated by any of the
above-mentioned companies. We act as an independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at:
www.FiveStarEquities.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Five Star Equities Email Contact
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024